Product Information
CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB is a generic product labeled by Sandoz Inc., priced at $0.8024 per EA under NDC 00781565401. Its NADAC has been published 602 times since Aug 20, 2014.
FDA first approved this application on Jun 11, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
37.5; 200; 150 mg/1; mg/1; mg/1
Manufacturer
Sandoz Inc.NDC
00781565401
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA; ENTACAPONE; LEVODOPAApproval Type
Authorized Generic (NDA)
FDA Application
NDA021485FDA Approved
6/11/2003
TE Code
AB
On Market Since
6/18/2014
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB has been published 602 times since Aug 20, 2014, and over the history we have for it it has declined 63.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8024 per EA |
|---|---|
| All-time high | $2.6143 (May 13, 2015) |
| All-time low | $0.5695 (Oct 18, 2023) |
| 52-week high | $0.8235 |
| 52-week low | $0.6401 |
| Median price | $1.0904 |
| Average price | $1.2830 |
| Largest weekly change | +51.5% (May 19, 2021) |
| Weeks tracked | 602 |
| Tracking since | Aug 20, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Carbidopa, Levodopa, and Entacapone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sandoz Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbidopa, Levodopa, and Entacapone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB, manufactured by Sandoz Inc., is $0.8024 per EA (NDC 00781565401), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB has declined 63.1%. It has been tracked across 602 weekly CMS publications since Aug 20, 2014.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?
Since Aug 20, 2014, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB has ranged from a low of $0.5695 (Oct 18, 2023) to a high of $2.6143 (May 13, 2015), with a median of $1.0904 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?
CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB (NDC 00781565401) is labeled by Sandoz Inc., and CMS classifies it as a generic product.